Skip to main content
SpringerLink
Log in

Hodgkin Lymphoma

  • Chapter
  • First Online:
60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center

  • 1166 Accesses

Abstract

An estimated 8,490 Americans were diagnosed as having Hodgkin lymphoma (HL) in 2010 [1]. HL is a B-cell lymphoma that arises from germinal center or post-germinal center B cells. Two types of classic HL (cHL) make up 95 % of HL diagnoses; in contrast, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is rare and has distinct pathologic features. cHL is unique in that the CD30-positive Reed–Sternberg (RS) cells often make up less than 1 % of the tumor and are surrounded by a rich microenvironment, including CD20-positive reactive B cells that are believed to provide survival signals to the RS cells.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.

    Article  PubMed  Google Scholar 

  2. Lister T, Crowther D, Sutcliffe S, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630–6 [published erratum appears in J Clin Oncol. 1990;8(9):1602].

    PubMed  CAS  Google Scholar 

  3. Specht L, Gray RG, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin’s disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin’s Disease Collaborative Group. J Clin Oncol. 1998;16:830–43.

    PubMed  CAS  Google Scholar 

  4. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol. 2004;22:2835–41.

    Article  PubMed  Google Scholar 

  5. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363:640–52.

    Article  PubMed  CAS  Google Scholar 

  6. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28:4199–206.

    Article  PubMed  Google Scholar 

  7. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348:2386–95.

    Article  PubMed  CAS  Google Scholar 

  8. Engert A, Franklin J, Mueller R-P, et al. HD12 randomised trial comparing 8 dose-escalated cycles of BEACOPP with 4 escalated and 4 baseline cycles in patients with advanced stage Hodgkin lymphoma (HL): an analysis of the German Hodgkin Lymphoma Study Group (GHSG), University of Cologne, D-50924 Cologne, Germany. ASH annual meeting abstracts. Blood. 2006;108:99.

    Google Scholar 

  9. Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood. 2008;112:3989–94.

    Article  PubMed  CAS  Google Scholar 

  10. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med. 1998;339:1506–14.

    Article  PubMed  CAS  Google Scholar 

  11. Copeland AR, Cao Y, Fanale M, et al. Final report of a phase-II study of rituximab plus ABVD for patients with newly diagnosed advanced stage classical Hodgkin lymphoma: results of long follow up and comparison to institutional historical data. ASH annual meeting abstracts. Blood. 2009;114:1680.

    Google Scholar 

  12. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.

    Article  PubMed  Google Scholar 

  13. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18 F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52.

    Article  PubMed  CAS  Google Scholar 

  14. Wirth A, Yuen K, Barton M, et al. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer. 2005;104:1221–9.

    Article  PubMed  Google Scholar 

  15. Nogova L, Reineke T, Eich HT, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol. 2005;16:1683–7. doi:10.1093/annonc/mdi323.

    Article  PubMed  CAS  Google Scholar 

  16. Chen RC, Chin MS, Ng AK, et al. Early-stage, lymphocyte-predominant Hodgkin’s lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol. 2010;28:136–41.

    Article  PubMed  Google Scholar 

  17. Al-Mansour M, Connors JM, Gascoyne RD, Skinnider B, Savage KJ. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin’s lymphoma. J Clin Oncol. 2010;28:793–9.

    Article  PubMed  Google Scholar 

  18. Fanale MA, Fayad L, Romaguera J, et al. Experience with R-CHOP in patients with lymphocyte predominant Hogdkin lymphoma (LPHL). Haematologica. 2007;92(s5):57.

    Google Scholar 

  19. Aparicio J, Segura A, Garcera S, et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol. 1999;10:593–5.

    Article  PubMed  CAS  Google Scholar 

  20. Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica. 2007;92:35–41.

    Article  PubMed  CAS  Google Scholar 

  21. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97:616–23.

    Article  PubMed  CAS  Google Scholar 

  22. Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol. 2007;18:1071–9.

    Article  PubMed  CAS  Google Scholar 

  23. Fanale MA, Fayad LE, Pro B, et al. A phase I study of bortezomib in combination with ICE (BICE) in patients with relapsed/refractory classical Hodgkin lymphoma. ASH annual meeting abstracts. Blood. 2008;112:3048.

    Article  Google Scholar 

  24. Popat U, Hosing C, Saliba RM, et al. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin’s lymphoma. Bone Marrow Transplant. 2004;33:1015–23.

    Article  PubMed  CAS  Google Scholar 

  25. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341:1051–4.

    Article  PubMed  CAS  Google Scholar 

  26. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359:2065–71.

    Article  PubMed  CAS  Google Scholar 

  27. Horning S, Fanale M, deVos S, et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort. 10th international conference on malignant lymphoma (10-ICML) [abstract 118]. Ann Oncol. 2008;19:iv120.

    Article  Google Scholar 

  28. Younes A, Forero-Torres A, Bartlett NL, et al. Multiple complete responses in a phase 1 dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas. ASH annual meeting abstracts. Blood. 2008;112:1006.

    Google Scholar 

  29. Fanale M, Bartlett NL, Forero-Torres A, et al. The antibody-drug conjugate brentuximab vedotin (SGN-35) induced multiple objective responses in patients with relapsed or refractory CD30-positive lymphomas in a phase 1 weekly dosing study. ASH annual meeting abstracts. Blood. 2009;114:2731.

    Google Scholar 

  30. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:1–7.

    Article  Google Scholar 

  31. Younes A, Pro B, Fanale M, et al. Isotype-selective HDAC inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical Hodgkin lymphoma (HL). ASH annual meeting abstracts. Blood. 2007;110:2566.

    Google Scholar 

  32. Younes A, Ong T-C, Ribrag V, et al. Efficacy of panobinostat in phase II study in patients with relapsed/refractory Hodgkin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant. ASH annual meeting abstracts. Blood. 2009;114:923.

    Google Scholar 

  33. Anderlini P, Champlin RE. Reduced intensity conditioning for allogeneic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: where do we stand? Biol Blood Marrow Transplant. 2006;12:599–602.

    Article  PubMed  Google Scholar 

  34. Peggs KS, Anderlini P, Sureda A. Allogeneic transplantation for Hodgkin lymphoma. Br J Haematol. 2008;143:468–80.

    PubMed  Google Scholar 

  35. Anderlini P, Saliba R, Acholonu S, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated MD Anderson Cancer Center experience. Haematologica. 2008;93:257–64.

    Article  PubMed  CAS  Google Scholar 

  36. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111:109–11.

    Article  PubMed  CAS  Google Scholar 

  37. Horning SJ, Bartlett NL, Breslin S, et al. Results of a prospective phase II trial of limited and extended rituximab treatment in Nodular Lymphocyte Predominant Hodgkin’s Disease (NLPHD). ASH annual meeting abstracts. Blood. 2007;110:644.

    Google Scholar 

  38. Popat U, Hosing C, Fanale M, et al. Autologous transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). ASH annual meeting abstracts. Blood. 2009;114:2310.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 429, Houston, TX, 77030, USA

    Michelle Fanale & Anas Younes

  2. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Bouthaina Dabaja

  3. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Uday Popat & Paolo Anderlini

Authors
  1. Michelle Fanale
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bouthaina Dabaja
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Uday Popat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paolo Anderlini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anas Younes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michelle Fanale .

Editor information

Editors and Affiliations

  1. Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA

    M. Alma Rodriguez

  2. Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA

    Ronald S. Walters

  3. Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA

    Thomas W. Burke

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Fanale, M., Dabaja, B., Popat, U., Anderlini, P., Younes, A. (2013). Hodgkin Lymphoma. In: Rodriguez, M., Walters, R., Burke, T. (eds) 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5197-6_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-5197-6_21

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-5196-9

  • Online ISBN: 978-1-4614-5197-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation